EUVIMEDEUVIMED entdecken
Open Access

Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment

Ling Luo, Junzhao Ye, Shuyu Zhuo, Bo Ma, Weiyi Mai, Xiaopei Cao, Liuqin Liang, Wei Wang, Shiting Feng, Zhi Dong, Bihui Zhong

Hepatobiliary Surgery and Nutrition · 2024-08 · 13 (4) · 632-649

DOI: 10.21037/hbsn-23-393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatobiliary Surgery and Nutrition, 2024-08. Verfasst von Ling Luo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High liver fat content (LFC) induces increased risks of both hepatic and extrahepatic progression in metabolic dysfunction-associated steatotic liver disease (MASLD), while maintaining a significant decline in magnetic resonance imaging-based proton density fat fraction (MRI-PDFF) (≥30% decline relative to baseline) without worsening fibrosis results in improved histological severity and prognosis. However, the factors associated with the loss of sustained responses to treatment remain unclear, and we aim to identify them.

Methods

Consecutive treatment-naïve MASLD patients between January 2015 and February 2022, with follow-up until April 2023, were included in this prospective cohort study. LFC quantified by MRI-PDFF and liver stiffness measurements (LSM) determined by two-dimensional shear wave elastography (2D-SWE) were evaluated at weeks 0, 24 and 48. MRI-PDFF response was defined as a ≥30% relative decline in PDFF values, and LSM response was defined as a ≥1 stage decline from baseline.

Results

A total of 602 MASLD patients were enrolled. Of the 303 patients with a 24-week MRI-PDFF response and complete follow-up of 48 weeks, the rate of loss of MRI-PDFF response was 29.4%, and multivariable logistic regression analyses showed that 24-week insulin resistance (IR), still regular exercise and caloric restriction after 24 weeks, and the relative decline in LFC were risk factors for loss of MRI-PDFF response. Loss of LSM response at 48 weeks occurred in 15.9% of patients, and multivariable analysis confirmed 24-week serum total bile acid (TBA) levels and the relative decline in TBA from baseline as independent predictors. No significant association was found at 48 weeks between loss of MRI-PDFF response and loss of LSM response.

Conclusions

MASLD patients with IR and high TBA levels are at higher risks of subsequent diminished sustained improvements of steatosis and fibrosis, respectively.

Schlagwörter

Stichwörter der Autor:innen

Metabolic dysfunction-associated steatotic liver disease (MASLD)liver stiffness measurements response (LSM response)loss of responsemagnetic resonance imaging-based proton density fat fraction response (MRI-PDFF…

Autor:innen und Institutionen

  • Department of Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Nutrition, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Gastroenterology, The East Division of the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Cardiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Endocrinology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
  • Department of Rheumatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.

Zitieren

APA

Luo, L., Ye, J., Zhuo, S., Ma, B., Mai, W., Cao, X., Liang, L., Wang, W., Feng, S., Dong, Z., & Zhong, B. (2024). Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment. Hepatobiliary Surgery and Nutrition, 13(4), 632-649. https://doi.org/10.21037/hbsn-23-393

Vancouver

Luo L, Ye J, Zhuo S, Ma B, Mai W, Cao X, et al. Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment. Hepatobiliary Surgery and Nutrition. 2024;13(4):632-649. doi:10.21037/hbsn-23-393

BibTeX
@article{Luo2024,
  author = {Luo, Ling and Ye, Junzhao and Zhuo, Shuyu and Ma, Bo and Mai, Weiyi and Cao, Xiaopei and Liang, Liuqin and Wang, Wei and Feng, Shiting and Dong, Zhi and Zhong, Bihui},
  title = {Specific metabolic impairments indicate loss of sustained liver improvements in metabolic dysfunction-associated steatotic liver disease treatment},
  journal = {Hepatobiliary Surgery and Nutrition},
  year = {2024},
  volume = {13},
  number = {4},
  pages = {632--649},
  doi = {10.21037/hbsn-23-393}
}
Kostenlos starten →